Stemline therapeutics inc (STML)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Income:
Cost of goods sold

4,893

-

-

-

-

-

-

-

-

Research and development

50,724

47,725

50,242

27,869

29,458

21,240

16,178

3,376

1,629

Selling, general and administrative

66,846

39,061

19,214

12,056

8,828

8,084

7,871

3,090

1,088

Total operating expenses

122,464

86,786

69,456

39,926

38,287

29,325

24,050

6,467

2,717

Loss from operations

-79,247

-86,286

-68,558

-38,885

-37,633

-28,989

-23,979

-6,467

-2,717

Other expense, net

-47

-7

-6

11

1

-

-

0

9

Other Income

-

-

-

-

-

3

280

301

46

Interest expense

34

0

-

-

-

-

516

118

98

Interest income

2,538

1,270

736

545

387

156

19

9

24

Net loss before income taxes

-76,791

-85,024

-67,828

-38,328

-37,243

-28,829

-24,196

-6,274

-2,754

Income tax (expense) benefit

-25

0

0

-25

0

-

-

-

-

Net loss

-76,817

-85,024

-67,828

-38,303

-37,243

-28,829

-

-

-2,754

Net loss per common share:
Basic and Diluted (in dollars per share)

-1.83

-2.99

-2.94

-2.15

-2.15

-2.23

-2.35

-1.82

-0.80

Weighted-average shares outstanding:
Basic and Diluted (in shares)

42,091

28,388

23,056

17,804

17,289

12,936

10,317

3,441

3,441

Product revenue, net
Revenue

43,216

500

898

1,041

654

335

71

-

-